AELIS FARMA overview

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, today announces its indicative financial calendar for the financial year 2025. Event Date of release* 2024 Annual Results Tuesday, April 1, 2025 Annual General Meeting Tuesday, May 27, 2025 2025 Half-Year Results Monday, September 22, 2025 (*) The press releases will be issued...

Regulatory News: Two videoconferences will be held tomorrow, on Tuesday November 19, 2024, the first in French at 10:00 am CET and the second in English at 4:00 pm CET / 10:00 am ET. To participate, please register here: Videoconference in French Videoconference in English Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, today announces the...

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces its participation in the 10 th Gordon Research Conference (GRC), taking place from July 16 to 21, 2023 in Barcelona, Spain. The GRC is a leading international scientific conference that aims to advance the frontiers of science through the presentation of cutting-edge research, with a focus on interaction between...

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announced that it has received a unanimous positive recommendation from the Data Safety Monitoring Board (DSMB) to continue, without modifying the protocol, the phase 2b clinical study with AEF0117 for the treatment of cannabis addiction. A DSMB is a committee of independent experts, specialized in clinical...

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that the availability of the description of the share buyback program authorized by the Annual General Meeting of May 24, 2023. Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized on May 24, 2023, in its 10 th resolution, the Board of...

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announced the presentation of new preclinical data on its drug candidate AEF0217 at the 2 nd European Conference on Phelan-McDermid Syndrome, which was held from June 9 to 11, 2023 at CEU San Pablo University in Madrid 1 . Phelan-McDermid Syndrome (PMS), which is caused by the deletion of chromosome 22q13 including...

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announced publication of a series of studies describing a new pharmacological class, cannabinoid receptor 1 signaling-specific inhibitors (CB 1 -SSi), and its first drug candidate, AEF0117, for the treatment of cannabis use disorder (CUD). The report, “ Signaling-specific inhibition of the CB 1 receptor for cannabis use...

Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders. Aelis Farma held its combined general meeting of shareholders on May 24, 2023, which was chaired by Mr. Anders Gersel Pedersen, Chairman of the Board of directors. With a quorum of 85%,...